RecruitingPhase 1NCT04319848

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty (TE-EK)

Sponsor

Singapore Eye Research Institute

Enrollment

30 participants

Start Date

Dec 1, 2017

Study Type

INTERVENTIONAL

Conditions

Fuchs' Endothelial Dystrophy Bullous Keratopathy Mild to Moderate Corneal Endothelial Decompensation Post-surgical Corneal Decompensation (Irreversible)

Summary

Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).

Eligibility

Min Age: 21 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying TE-EK treatment group for people with bullous keratopathy, fuchs' endothelial dystrophy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTE-EK treatment group

Transplantation of tissue-engineered endothelial graft through DSAEK procedure.

Locations(1)

Singapore Eye Research Institute

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04319848

Related Trials

Descemet Endothelial Thickness Comparison Trial II

NCT052759728 locations

Simple Non-cultured Endothelial Cell Therapy for Corneal Endothelial Dysfunction

NCT077115611 location